Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

-- Quarter Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch --

EXTON, Pa., Feb. 24 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2008.

Key events since September 30, 2008 include:

Operational:

  • Closed on acquisition of Lev Pharmaceuticals, Inc. (Lev) in October 2008;
  • Initiated commercial launch of Cinryze for routine prophylaxis of hereditary angioedema (HAE);
  • Developed and successfully launched Cinryze patient access program, CinryzeSolutions(TM);
  • Launched new sales team in December for Cinryze;
  • Achieved net Vancocin(R) sales of $50 million during fourth quarter 2008; and
  • Increased research and development expenses by 70 percent over the fourth quarter of 2007, primarily driven by maribavir and Cinryze.

Development:

  • Filed supplemental Biologics License Application (sBLA) for Cinryze for treatment of acute attacks of HAE;
  • Granted priority review by the U.S. Food and Drug Administration for Cinryze sBLA for treatment of acute attacks of HAE, with a Prescription Drug User Fee Act (PDUFA) date of June 3, 2009; and
  • Discontinued maribavir clinical development program for prophylaxis against cytomegalovirus disease in transplant patients based on the preliminary analysis of phase 3 data.

Financial Results:

  • Achieved 16th consecutive quarter of positive cash flows from operations; and
  • Ended 2008 with working capital of $305 million, which includes cash, cash equivalents and short-term investments of $276 mi
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 The prestigious "Discovery or Exploration ... recently awarded to Juliana Hillis and Kaylie O’Connell, students ... project, “From an Egg, Everything: America’s First IVF Baby". ... for the National History Day program during a week-long ... educators in Washington, D.C. , The growing popularity of ...
(Date:7/29/2014)... EXpressLO LLC, expert provider of focused ... solutions, has been granted patent number 8,789,826 by the ... incorporating a unique specimen carrier support grid design described ... company patent for EXpressLO LLC awarded to founder and ... complementary patents extend EXpressLO’s portfolio of intellectual property. The ...
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
(Date:7/28/2014)... According to a new market research ... (Bone and Joint) Market (By Technology - Stem ... - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, ... Size, Share, Growth, Trends and Forecast, 2013 - ... market was valued at USD 2.6 billion in ...
Breaking Biology Technology:In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... Chicago-based Celsis International, a leading global life sciences company, ... process and will de-list from the London Stock Exchange ... "Celsis has a very strong track record of consistent ... results were not being reflected in our share price," ...
... N.J., Oct. 9 Soligenix, Inc. (Soligenix or the ... announced today that Robert J. Rubin, MD, has been ... has had a distinguished career in the healthcare industry ... as president of the national health policy and management ...
... WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... Cormack, president and chief executive officer of OncoGenex, has ... The Year(R). The Ernst & Young Entrepreneur Of The ... entrepreneurs that are building successful, dynamic businesses. , "I ...
Cached Biology Technology:Chicago-Based Celsis International Goes Private 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 4OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 2OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 3
(Date:7/28/2014)... John Essigmann and colleagues from the University of Washington had ... they could induce the virus to mutate uncontrollably, they could ... strategy that our immune system uses against many viruses. ... to mutate at an enhanced rate, as expected. But it ... clinical trial reported in 2011. In a new study, however, ...
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
(Date:7/28/2014)... himself the bug hunter, but the target of his ... and identified with special methods and instruments. Benjamin Hause, ... Diagnostic Laboratory at Kansas State University, recently published an ... which is an important find in the United States. ... didn,t know what it was," Hause said. "We used ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... Researchers at the University of Cambridge have discovered a ... within the body, a breakthrough that could lead to ... , Dr. Pietro Mastroeni, Professor Duncan Maskell at ... pioneered the integration of mathematical models with observational data ...
... had narrow, pointed teeth, which were more suited to tearing ... then grind their food? Until recently many researchers have assumed ... their muscular stomach these then acted as a kind of ... correct, as scientists at the universities of Bonn and Tübingen ...
... regulate neuronal signaling in the brain and spinal cord ... mouse with a mutation affecting a neuronal zinc target, ... modulating signaling among the neurons. Significantly, they found the ... as children with the genetic disorder called "startle disease," ...
Cached Biology News:Researchers map spread of pathogens in the human body 2Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3Zinc plays important role in brain circuitry 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Request Info...
Biology Products: